Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kaken to Acquire Takeda Spinout to Expand Development Pipeline
December 1, 2021
- Taiho Exercises Option to Grab Arcus’ Anti-TIGIT Antibodies
December 1, 2021
- Takeda to Succeed Fabry Disease Med from Sumitomo Dainippon
December 1, 2021
- Blaze at Hitachi Logistic Center Could Add to Drug Supply Woes
December 1, 2021
- BMS Files Psoriasis Drug Deucravacitinib in Japan
December 1, 2021
- Astellas’ ADC Padcev Now Available in Japan
December 1, 2021
- Takeda Rolls Out Crohn’s Disease Cell Therapy Alofisel in Japan
December 1, 2021
- Lenvima/Keytruda Bags EU Approval for RCC, Endometrial Carcinoma
November 30, 2021
- Japan Makers Racing to Study Vaccines for Omicron Variant
November 30, 2021
- Takeda Seeks Japan Approval for Low-Dose Revestive
November 29, 2021
- Sanofi’s Pompe Disease Drug Nexviazyme Now Available in Japan
November 29, 2021
- AbbVie Japan Rolls Out New Dosage Forms for Rinvoq, Skyrizi
November 29, 2021
- Daiichi Sankyo Sets Up New Subsidiaries in 3 Countries
November 29, 2021
- Takeda’s GI Biz Poised for Growth with 3 Products Now in Its Lineup
November 29, 2021
- MSD Japan Hails Resumption of HPV Vaccine Recommendation
November 29, 2021
- Shionogi, Vietnam Discuss Tech Transfer of COVID-19 Vaccine
November 26, 2021
- J-TEC to Start Study of Allogeneic Cultured Epidermis for DDB Patients
November 26, 2021
- Kowa Files Glanatec Combo for Glaucoma, Ocular Hypertension in Japan
November 26, 2021
- AstraZeneca’s Lupus Med, 3rd Humira Biosimilar Now Available in Japan
November 26, 2021
- Shionogi Pharma, 5 Other Firms to Form Continuous Manufacturing JV
November 25, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…